Wolverine Trading’s 10x Genomics TXG Stock Holding History

Wolverine Trading’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-939,091	Closed	-$34.2M	–	4982
2022 Q4	$34.2M	Buy	+939,091	New	+$30.7M	0.05%	285

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Wolverine Trading's TXG Position: Q1 2023 in Review

Wolverine Trading sold out of 10x Genomics (TXG) in Q1 2023, closing a stake of 939,091 shares — an estimated $34.2M sold.

Wolverine Trading first reported a position in TXG in Q4 2022 and held it in 1 quarter. The position peaked at $34.2M in Q4 2022. 258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

Wolverine Trading reported no remaining 10x Genomics position as of Q1 2023 after selling out during the quarter.
Wolverine Trading sold 939,091 10x Genomics shares in Q1 2023, an estimated $34.2M.
Wolverine Trading first reported a position in 10x Genomics in Q4 2022 and held it in 1 quarter.
Wolverine Trading's 10x Genomics position peaked at $34.2M in Q4 2022.
258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on Wolverine Trading's 13F filing for Q1 2023, filed 15 May 2023.